U.S. FDA grants priority review to Roche's bispecific antibody Glofitamab

[January 06, 2023]  ZURICH (Reuters) - Roche announced on Friday the U.S. Food and Drug Administration has granted priority review to the Swiss pharmaceutical company's bispecific antibody Glofitamab.

Glofitamab is intended for patients with relapsed or refractory large b-cell lymphoma.

The FDA is expected to make a decision on approval of the cancer immunotherapy by July 1, 2023.
 

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo

(Reporting by Noele Illien; Editing by Tom Hogue)

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.